Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices

Hugo G. Schmoekel, Franz E. Weber, Jason C. Schense, Klaus W. Grätz, Peter Schawalder, Jeffrey A. Hubbell

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Most growth factors naturally involved in development and regeneration demonstrate strong binding to the extracellular matrix and are retained there until being locally mobilized by cells. In spite of this feedback between cell activity and growth factor mobilization in the extracellular matrix, this approach has not been extensively explored in therapeutic situations. We present an engineered bone morphogenetic protein-2 (BMP-2) fusion protein that mimics such function in a surgically relevant matrix, fibrin, incorporated into the matrix until it is locally liberated by cell surface-associated proteases. A tripartite fusion protein, denoted TG-pl-BMP-2, was designed and produced recombinantly. An N-terminal transglutaminase substrate (TG) domain provides covalent attachment to fibrin during coagulation under the influence of the blood transglutaminase factor XIIIa. A central plasmin substrate (pl) domain provides a cleavage site for local release of the attached growth factor from the fibrin matrix under the influence of cell-activated plasmin. A C-terminal human BMP-2 domain provides osteogenic activity. TG-pl-BMP-2 in fibrin was evaluated in vivo in critical-size craniotomy defects in rats, where it induced 76% more defect healing with bone at 3 weeks with a dose of 1 μg/defect than wildtype BMP-2 in fibrin. After a dosing study in rabbits, the engineered growth factor in fibrin was evaluated in a prospective clinical study for pancarpal fusion in dogs, where it induced statistically faster and more extensive bone bridging than equivalent treatment with cancellous bone autograft. The strong healing response shown by fibrin including a bound BMP-2 variant suggests that with the combination of bound growth factor and ingrowth matrix, it may be possible to improve upon the natural growth factor and even upon tissue autograft.

Original languageEnglish
Pages (from-to)253-262
Number of pages10
JournalBiotechnology and Bioengineering
Volume89
Issue number3
DOIs
StatePublished - Feb 5 2005
Externally publishedYes

Fingerprint

Bone Morphogenetic Protein 2
Fibrin
Bone
Repair
Intercellular Signaling Peptides and Proteins
Transglutaminases
Proteins
Bone and Bones
Fusion reactions
Fibrinolysin
Autografts
Substrates
Defects
Extracellular Matrix
Factor XIIIa
Craniotomy
Coagulation
Rats
Regeneration
Blood

Keywords

  • BMP-2
  • Bone regeneration
  • Drug release
  • Fibrin
  • Tissue engineering

ASJC Scopus subject areas

  • Biotechnology
  • Microbiology

Cite this

Schmoekel, H. G., Weber, F. E., Schense, J. C., Grätz, K. W., Schawalder, P., & Hubbell, J. A. (2005). Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices. Biotechnology and Bioengineering, 89(3), 253-262. https://doi.org/10.1002/bit.20168

Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices. / Schmoekel, Hugo G.; Weber, Franz E.; Schense, Jason C.; Grätz, Klaus W.; Schawalder, Peter; Hubbell, Jeffrey A.

In: Biotechnology and Bioengineering, Vol. 89, No. 3, 05.02.2005, p. 253-262.

Research output: Contribution to journalArticle

Schmoekel, HG, Weber, FE, Schense, JC, Grätz, KW, Schawalder, P & Hubbell, JA 2005, 'Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices', Biotechnology and Bioengineering, vol. 89, no. 3, pp. 253-262. https://doi.org/10.1002/bit.20168
Schmoekel, Hugo G. ; Weber, Franz E. ; Schense, Jason C. ; Grätz, Klaus W. ; Schawalder, Peter ; Hubbell, Jeffrey A. / Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices. In: Biotechnology and Bioengineering. 2005 ; Vol. 89, No. 3. pp. 253-262.
@article{939e97273ec0407b8961e13f279c2aeb,
title = "Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices",
abstract = "Most growth factors naturally involved in development and regeneration demonstrate strong binding to the extracellular matrix and are retained there until being locally mobilized by cells. In spite of this feedback between cell activity and growth factor mobilization in the extracellular matrix, this approach has not been extensively explored in therapeutic situations. We present an engineered bone morphogenetic protein-2 (BMP-2) fusion protein that mimics such function in a surgically relevant matrix, fibrin, incorporated into the matrix until it is locally liberated by cell surface-associated proteases. A tripartite fusion protein, denoted TG-pl-BMP-2, was designed and produced recombinantly. An N-terminal transglutaminase substrate (TG) domain provides covalent attachment to fibrin during coagulation under the influence of the blood transglutaminase factor XIIIa. A central plasmin substrate (pl) domain provides a cleavage site for local release of the attached growth factor from the fibrin matrix under the influence of cell-activated plasmin. A C-terminal human BMP-2 domain provides osteogenic activity. TG-pl-BMP-2 in fibrin was evaluated in vivo in critical-size craniotomy defects in rats, where it induced 76{\%} more defect healing with bone at 3 weeks with a dose of 1 μg/defect than wildtype BMP-2 in fibrin. After a dosing study in rabbits, the engineered growth factor in fibrin was evaluated in a prospective clinical study for pancarpal fusion in dogs, where it induced statistically faster and more extensive bone bridging than equivalent treatment with cancellous bone autograft. The strong healing response shown by fibrin including a bound BMP-2 variant suggests that with the combination of bound growth factor and ingrowth matrix, it may be possible to improve upon the natural growth factor and even upon tissue autograft.",
keywords = "BMP-2, Bone regeneration, Drug release, Fibrin, Tissue engineering",
author = "Schmoekel, {Hugo G.} and Weber, {Franz E.} and Schense, {Jason C.} and Gr{\"a}tz, {Klaus W.} and Peter Schawalder and Hubbell, {Jeffrey A.}",
year = "2005",
month = "2",
day = "5",
doi = "10.1002/bit.20168",
language = "English",
volume = "89",
pages = "253--262",
journal = "Biotechnology and Bioengineering",
issn = "0006-3592",
publisher = "Wiley-VCH Verlag",
number = "3",

}

TY - JOUR

T1 - Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices

AU - Schmoekel, Hugo G.

AU - Weber, Franz E.

AU - Schense, Jason C.

AU - Grätz, Klaus W.

AU - Schawalder, Peter

AU - Hubbell, Jeffrey A.

PY - 2005/2/5

Y1 - 2005/2/5

N2 - Most growth factors naturally involved in development and regeneration demonstrate strong binding to the extracellular matrix and are retained there until being locally mobilized by cells. In spite of this feedback between cell activity and growth factor mobilization in the extracellular matrix, this approach has not been extensively explored in therapeutic situations. We present an engineered bone morphogenetic protein-2 (BMP-2) fusion protein that mimics such function in a surgically relevant matrix, fibrin, incorporated into the matrix until it is locally liberated by cell surface-associated proteases. A tripartite fusion protein, denoted TG-pl-BMP-2, was designed and produced recombinantly. An N-terminal transglutaminase substrate (TG) domain provides covalent attachment to fibrin during coagulation under the influence of the blood transglutaminase factor XIIIa. A central plasmin substrate (pl) domain provides a cleavage site for local release of the attached growth factor from the fibrin matrix under the influence of cell-activated plasmin. A C-terminal human BMP-2 domain provides osteogenic activity. TG-pl-BMP-2 in fibrin was evaluated in vivo in critical-size craniotomy defects in rats, where it induced 76% more defect healing with bone at 3 weeks with a dose of 1 μg/defect than wildtype BMP-2 in fibrin. After a dosing study in rabbits, the engineered growth factor in fibrin was evaluated in a prospective clinical study for pancarpal fusion in dogs, where it induced statistically faster and more extensive bone bridging than equivalent treatment with cancellous bone autograft. The strong healing response shown by fibrin including a bound BMP-2 variant suggests that with the combination of bound growth factor and ingrowth matrix, it may be possible to improve upon the natural growth factor and even upon tissue autograft.

AB - Most growth factors naturally involved in development and regeneration demonstrate strong binding to the extracellular matrix and are retained there until being locally mobilized by cells. In spite of this feedback between cell activity and growth factor mobilization in the extracellular matrix, this approach has not been extensively explored in therapeutic situations. We present an engineered bone morphogenetic protein-2 (BMP-2) fusion protein that mimics such function in a surgically relevant matrix, fibrin, incorporated into the matrix until it is locally liberated by cell surface-associated proteases. A tripartite fusion protein, denoted TG-pl-BMP-2, was designed and produced recombinantly. An N-terminal transglutaminase substrate (TG) domain provides covalent attachment to fibrin during coagulation under the influence of the blood transglutaminase factor XIIIa. A central plasmin substrate (pl) domain provides a cleavage site for local release of the attached growth factor from the fibrin matrix under the influence of cell-activated plasmin. A C-terminal human BMP-2 domain provides osteogenic activity. TG-pl-BMP-2 in fibrin was evaluated in vivo in critical-size craniotomy defects in rats, where it induced 76% more defect healing with bone at 3 weeks with a dose of 1 μg/defect than wildtype BMP-2 in fibrin. After a dosing study in rabbits, the engineered growth factor in fibrin was evaluated in a prospective clinical study for pancarpal fusion in dogs, where it induced statistically faster and more extensive bone bridging than equivalent treatment with cancellous bone autograft. The strong healing response shown by fibrin including a bound BMP-2 variant suggests that with the combination of bound growth factor and ingrowth matrix, it may be possible to improve upon the natural growth factor and even upon tissue autograft.

KW - BMP-2

KW - Bone regeneration

KW - Drug release

KW - Fibrin

KW - Tissue engineering

UR - http://www.scopus.com/inward/record.url?scp=14244268881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14244268881&partnerID=8YFLogxK

U2 - 10.1002/bit.20168

DO - 10.1002/bit.20168

M3 - Article

C2 - 15619323

AN - SCOPUS:14244268881

VL - 89

SP - 253

EP - 262

JO - Biotechnology and Bioengineering

JF - Biotechnology and Bioengineering

SN - 0006-3592

IS - 3

ER -